Evidence map›Paper›PMID 30912341›Full record

SynthesisEndocrinology and metabolism (Seoul, Korea)2019

Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Jae Hyun Bae, Sunhee Kim, Eun Gee Park, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim

Open access · diamondAbstract readComparative StudyMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Endocrinology and metabolism (Seoul, Korea), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022
    Article
  19. Article
  20. Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jae Hyun Bae *Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.ORCID 0000-0002-1384-6123
Sunhee Kim *Interdisciplinary Program in Medical Informatics, Seoul National University College of Medicine, Seoul, Korea.
Eun Gee ParkInterdisciplinary Program in Medical Informatics, Seoul National University College of Medicine, Seoul, Korea.
Sin Gon KimDepartment of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Seokyung HahnDivision of Medical Statistics, Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-4684-4917
Nam Hoon KimDepartment of Internal Medicine, Korea University College of Medicine, Seoul, Korea. pourlife@korea.ac.kr.ORCID 0000-0002-9926-1344
Seoul National University · KRKorea University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal outcomes in patients with type 2 diabetes.

methodsMEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched to identify randomized controlled trials (RCTs) of DPP-4 inhibitors from inception to September 2017. We selected eligible RCTs comparing DPP-4 inhibitors with placebo or other antidiabetic agents and reporting at least one renal outcome. A meta-analysis was conducted to calculate standardized mean differences, weighted mean differences (WMDs), relative risks (RRs), and 95% confidence intervals (CIs) for each renal outcome.

resultsWe included 23 RCTs with 19 publications involving 41,359 patients. Overall changes in urine albumin-to-creatinine ratio were comparable between DPP-4 inhibitors and controls (

conclusionDPP-4 inhibitors had beneficial renal effects mainly by reducing the risk of development or progression of albuminuria compared with placebo or other antidiabetic agents.

Indexed as

AgedAlbuminsAlbuminuriaDiabetes ComplicationsDiabetes Mellitus, Type 2Diabetic NephropathiesDipeptidyl-Peptidase IV InhibitorsGlomerular Filtration RateHumansHypoglycemic AgentsKidneyKidney Failure, ChronicMiddle AgedPlacebosRandomized Controlled Trials as TopicAlbuminsDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsPlacebosAlbuminuriaDiabetes complicationsDiabetes mellitus, type 2Diabetic nephropathiesDipeptidyl-peptidase IV inhibitorsGlomerular filtration rateKidney failure, chronicMeta-analysisSystematic review

Identifiers

PMID30912341
PMCPMC6435854
OpenAlexW2927910672

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.